A pilot trial of pramlintide home usage in adolescents with type 1 diabetes.

Kishiyama CM, Burdick PL, Cobry EC, Gage VL, Messer LH, McFann K, Chase HP

Pediatrics26 Oct 2009Cited by 13 (Europe PMC)

PMID19858155DOI10.1542/peds.2008-3750PepBankPUB-19858155

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adolescents with type 1 diabetes, pramlintide reduced HbA1c compared with control.
In plain wordsIn adolescents with type 1 diabetes, pramlintide reduced HbA1c more than control.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseHbA1c
Study
n = 10
Comparator
Control group
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Maximum 30 microg per meal · 28 daysAs given in this study (human).
Source sentences
Summary
Changes in HbA1c values, body weight, and total insulin dose declined in the treatment group compared with the control group (bootstrapped, P <or= .02 for each).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a randomized, 28-day pilot trial of pramlintide (maximum dose: 30 microg per meal) in 10 adolescents aged 13 to 17 years.
Report a problemFND-1985815501
02HumanRandomized controlled trialEfficacy outcome
In adolescents with type 1 diabetes, pramlintide reduced body weight compared with control.
In plain wordsIn adolescents with type 1 diabetes, pramlintide reduced weight more than control.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBody weight
Study
n = 10
Comparator
Control group
Outcome group
Body weight · Metabolic and weight
Studied dose
Maximum 30 microg per meal · 28 daysAs given in this study (human).
Source sentences
Summary
Changes in HbA1c values, body weight, and total insulin dose declined in the treatment group compared with the control group (bootstrapped, P <or= .02 for each).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a randomized, 28-day pilot trial of pramlintide (maximum dose: 30 microg per meal) in 10 adolescents aged 13 to 17 years.
Report a problemFND-1985815502
03HumanRandomized controlled trialEfficacy outcome
In adolescents with type 1 diabetes, pramlintide reduced total insulin dose compared with control.
In plain wordsIn adolescents with type 1 diabetes, pramlintide reduced total insulin dose more than control.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseTotal insulin dose
Study
n = 10
Comparator
Control group
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Maximum 30 microg per meal · 28 daysAs given in this study (human).
Source sentences
Summary
Changes in HbA1c values, body weight, and total insulin dose declined in the treatment group compared with the control group (bootstrapped, P <or= .02 for each).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a randomized, 28-day pilot trial of pramlintide (maximum dose: 30 microg per meal) in 10 adolescents aged 13 to 17 years.
Report a problemFND-1985815503
04HumanRandomized controlled trialEfficacy outcome
In adolescents with type 1 diabetes, pramlintide lowered average dinner glucose AUC compared with control.
In plain wordsIn adolescents with type 1 diabetes, pramlintide lowered average glucose exposure after dinner compared with control.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseDinner glucose AUC
Study
n = 10
Comparator
Control group
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Maximum 30 microg per meal · 28 daysAs given in this study (human).
Source sentences
Summary
The treatment group also demonstrated lower average dinner area under the curve (P = .02) and lower maximum breakfast (P = .03) and dinner (P = .02) postprandial blood glucose values.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a randomized, 28-day pilot trial of pramlintide (maximum dose: 30 microg per meal) in 10 adolescents aged 13 to 17 years.
Report a problemFND-1985815504
05HumanRandomized controlled trialEfficacy outcome
In adolescents with type 1 diabetes, pramlintide lowered maximum postprandial breakfast glucose compared with control.
In plain wordsIn adolescents with type 1 diabetes, pramlintide lowered peak glucose after breakfast compared with control.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseBreakfast peak glucose
Study
n = 10
Comparator
Control group
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Maximum 30 microg per meal · 28 daysAs given in this study (human).
Source sentences
Summary
The treatment group also demonstrated lower average dinner area under the curve (P = .02) and lower maximum breakfast (P = .03) and dinner (P = .02) postprandial blood glucose values.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a randomized, 28-day pilot trial of pramlintide (maximum dose: 30 microg per meal) in 10 adolescents aged 13 to 17 years.
Report a problemFND-1985815505
06HumanRandomized controlled trialEfficacy outcome
In adolescents with type 1 diabetes, pramlintide lowered maximum postprandial dinner glucose compared with control.
In plain wordsIn adolescents with type 1 diabetes, pramlintide lowered peak glucose after dinner compared with control.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseDinner peak glucose
Study
n = 10
Comparator
Control group
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Maximum 30 microg per meal · 28 daysAs given in this study (human).
Source sentences
Summary
The treatment group also demonstrated lower average dinner area under the curve (P = .02) and lower maximum breakfast (P = .03) and dinner (P = .02) postprandial blood glucose values.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a randomized, 28-day pilot trial of pramlintide (maximum dose: 30 microg per meal) in 10 adolescents aged 13 to 17 years.
Report a problemFND-1985815506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableResults postedNCT00842075

Pramlintide in Adolescents With Type 1 Diabetes

University of Colorado, Denvern = 10Dec 2006 to Dec 2009

Type 1 Diabetes

Trial page ClinicalTrials.govUpdated 23 Jun 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.